References
- World Health Organization. WHO coronavirus (COVID-19) dashboard [Internet]. Geneva: World Health Organization; 2021 [cited 2022 May 11]. Available from: https://covid19.who.int.
- Centers for Disease Control and Prevention. COVID data tracker [Internet]. Atlanta: Centers for Disease Control and Prevention; 2021 [cited 2022 Apr 20]. Available from: https://covid.cdc.gov/covid-datatracker/#demographicsovertime.
- World Health Organization. COVID-19 vaccine tracker and landscape [Internet]. Geneva: World Health Organization; 2021 [cited 2022 May 25]. Available from: https://www.who.int/publications/m/item/draftlandscape-of-covid-19-candidate-vaccines.
- Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021;384:1412-23. https://doi.org/10.1056/NEJMoa2101765
- Centers for Disease Control and Prevention. The coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network [Internet]. Atlanta: Centers for Disease Control and Prevention; 2021 [cited 2022 Jun 1]. Available from: https://gis.cdc.gov/grasp/COVIDNet/COVID19_3.html.
- American Academy of Pediatrics. Children and COVID-19: state-level data report [Internet]. Itasca: American Academy of Pediatrics; 2021 [cited 2022 May 3]. Available from: https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report.
- European Centre for Disease Prevention and Control. COVID-19 in children and the role of school settings in transmission - second update [Internet]. Solna: European Centre for Disease Prevention and Control; 2021 [cited 2022 Jun 30]. Available from: https://www.ecdc.europa.eu/en/publications-data/children-andschool-settings-covid-19-transmission.
- Delahoy MJ, Ujamaa D, Whitaker M, O'Halloran A, Anglin O, Burns E, et al. Hospitalizations associated with COVID-19 among children and adolescents - COVID-NET, 14 States, March 1, 2020-August 14, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1255-60. https://doi.org/10.15585/mmwr.mm7036e2
- VIPER Group COVID19 Vaccine Tracker Team. COVID-19 vaccine tracker [Internet]. [place unknown]: VIPER Group COVID19 Vaccine Tracker Team; 2021 [cited 2022 May 3]. Available from: https://covid19.trackvaccines.org.
- World Health Organization. COVID-19 vaccines, WHO's emergency use listing [Internet]. Geneva: World Health Organization; 2021 [cited 2022 May 4]. Available from: https://extranet.who.int/pqweb/vaccines/covid-19-vaccines.
- U.S Food & Drug Administration. FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic [Internet]. Silver Spring: U.S Food & Drug Administration; 2021 [cited 2022 May 4]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccineemergency-use.
- European Medicines Agency. First COVID-19 vaccine approved for children aged 12 to 15 in EU [Internet]. Amsterdam: European Medicines Agency; 2021 [cited 2022 May 5]. Available from: https://www.ema. europa.eu/en/news/first-covid-19-vaccine-approved-children-aged-12-15-eu.
- Au WY, Cheung PP. Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. BMJ 2022;377:e069989.
- Higdon MM, Wahl B, Jones CB, Rosen JG, Truelove SA, Baidya A, et al. A systematic review of coronavirus disease 2019 vaccine efficacy and effectiveness against severe acute respiratory syndrome coronavirus 2 infection and disease. Open Forum Infect Dis 2022;9:ofac138.
- Kouhpayeh H, Ansari H. Adverse events following COVID-19 vaccination: a systematic review and metaanalysis. Int Immunopharmacol 2022;109:108906.
- Haas JW, Bender FL, Ballou S, Kelley JM, Wilhelm M, Miller FG, et al. Frequency of adverse events in the placebo arms of COVID-19 vaccine trials: a systematic review and meta-analysis. JAMA Netw Open 2022;5:e2143955.
- Lee AS, Balakrishnan ID, Khoo CY, Ng CT, Loh JK, Chan LL, et al. Myocarditis following COVID-19 vaccination: a systematic review (October 2020-October 2021). Heart Lung Circ 2022;31:757-65. https://doi.org/10.1016/j.hlc.2022.02.002
- Park DY, An S, Kaur A, Malhotra S, Vij A. Myocarditis after COVID-19 mRNA vaccination: a systematic review of case reports and case series. Clin Cardiol 2022;45:691-700. https://doi.org/10.1002/clc.23828
- Tian F, Yang R, Chen Z. Safety and efficacy of COVID-19 vaccines in children and adolescents: a systematic review of randomized controlled trials. J Med Virol 2022;94:4644-53. https://doi.org/10.1002/jmv.27940
- Chen M, Yuan Y, Zhou Y, Deng Z, Zhao J, Feng F, et al. Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials. Infect Dis Poverty 2021;10:94.
- Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
- Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev 2019;10:ED000142.
- Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. 2nd ed. Chichester: John Wiley & Sons, 2019.
- Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M, et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N Engl J Med 2021;385:2241-51. https://doi.org/10.1056/NEJMoa2109522
- Frenck RW Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents. N Engl J Med 2021;385:239-50. https://doi.org/10.1056/NEJMoa2107456
- Dorabawila V, Hoefer D, Bauer UE, Bassett MT, Lutterloh E, Rosenberg ES. Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the emergence of the Omicron variant. medRxiv, in press 2022.
- Fleming-Dutra KE, Britton A, Shang N, Derado G, Link-Gelles R, Accorsi EK, et al. Association of prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during Omicron predominance. JAMA 2022;327:2210-9. https://doi.org/10.1001/jama.2022.7493
- Glatman-Freedman A, Hershkovitz Y, Kaufman Z, Dichtiar R, Keinan-Boker L, Bromberg M. Effectiveness of BNT162b2 vaccine in adolescents during outbreak of SARS-CoV-2 Delta variant infection, Israel, 2021. Emerg Infect Dis 2021;27:2919-22. https://doi.org/10.3201/eid2711.211886
- Husin M, Tok PS, Suah JL, Thevananthan T, Tng BH, Peariasamy KM, et al. Real-world effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection among adolescents (12 to 17-year-olds) in Malaysia. Int J Infect Dis 2022;121:55-7. https://doi.org/10.1016/j.ijid.2022.04.053
- Choe YJ, Yi S, Hwang I, Kim J, Park YJ, Cho E, et al. Safety and effectiveness of BNT162b2 mRNA COVID-19 vaccine in adolescents. Vaccine 2022;40:691-4. https://doi.org/10.1016/j.vaccine.2021.12.044
- Lai FT, Chua GT, Chan EW, Huang L, Kwan MY, Ma T, et al. Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study. Emerg Microbes Infect 2022;11:885-93. https://doi.org/10.1080/22221751.2022.2050952
- Li X, Lai FT, Chua GT, Kwan MY, Lau YL, Ip P, et al. Myocarditis following COVID-19 BNT162b2 vaccination among adolescents in Hong Kong. JAMA Pediatr 2022;176:612-4. https://doi.org/10.1001/jamapediatrics.2022.0101
- Nygaard U, Holm M, Bohnstedt C, Chai Q, Schmidt LS, Hartling UB, et al. Population-based incidence of myopericarditis after COVID-19 vaccination in Danish adolescents. Pediatr Infect Dis J 2022;41:e25-8. https://doi.org/10.1097/INF.0000000000003389
- Oliveira CR, Niccolai LM, Sheikha H, Elmansy L, Kalinich CC, Grubaugh ND, et al. Assessment of clinical effectiveness of BNT162b2 COVID-19 vaccine in US adolescents.JAMA Netw Open 2022;5;e220935.
- Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al. Myocarditis cases reported after mRNAbased COVID-19 vaccination in the US from December 2020 to August 2021. JAMA 2022;327:331-40. https://doi.org/10.1001/jama.2021.24110
- Ouldali N, Bagheri H, Salvo F, Antona D, Pariente A, Leblanc C, et al. Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children: a national post-authorization pharmacovigilance study. Lancet Reg Health Eur 2022;17:100393.
- Powell AA, Kirsebom F, Stowe J, McOwat K, Saliba V, Ramsay ME, et al. Effectiveness of BNT162b2 against COVID-19 in adolescents. Lancet Infect Dis 2022;22:581-3. https://doi.org/10.1016/S1473-3099(22)00177-3
- Price AM, Olson SM, Newhams MM, Halasa NB, Boom JA, Sahni LC, et al. BNT162b2 protection against the Omicron variant in children and adolescents. N Engl J Med 2022;30:30.
- Veneti L, Berild JD, Watle SV, Starrfelt J, Greve-Isdahl M, Langlete P, et al. Vaccine effectiveness with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine against reported SARS-CoV-2 Delta and Omicron infection among adolescents, Norway, August 2021 to January 2022. medRxiv, in press 2022.
- Kim ST, Hwang IS, Go MJ, Kim HJ, Park KE, Cho SY, et al. Status of adverse reaction monitoring after COVID-19 vaccination in children and adolescents (12 to 17 years old).Public Health Wkly Rep 2021;14:3542-8.
- Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. Myocarditis after COVID-19 vaccination in a large health care organization. N Engl J Med 2021;385:2132-9. https://doi.org/10.1056/NEJMoa2110737
- Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices - United States, June 2021. MMWR Morb Mortal Wkly Rep 2021;70:977-82. https://doi.org/10.15585/mmwr.mm7027e2
- Hwang IS, Song JS, Seo SY, Kim Y, Lee YK, et al.Status of adverse reactions after COVID-19 vaccination in third-year high school students. Public Health Wkly Rep 2021;14:2796-802.
- National Library of Medicine. ClinicalTrials.gov [Internet]. Bethesda: National Library of Medicine; 2021 [cited 2022 May 10]. Available from: https://clinicaltrials.gov/ct2/results?cond=covid-19+vaccines&age_v=&age=0&gndr=&type=&rslt=&phase=2&phase=3&Search=Apply.
- Pfizer. Pfizer and BioNTech announce positive topline results from pivotal trial of COVID-19 vaccine in children 5 to 11 years [Internet]. New York: Pfizer; 2021 [cited 2022 Jun 3]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-topline-results.
- Committee on Infectious Diseases. COVID-19 vaccines in children and adolescents. Pediatrics 2021;148:e2021052336.
- Public Health Agency of Canada. National Advisory Committee on Immunization. mRNA COVID-19 vaccines in adolescents 12 to 17 years of age: NACI recommendation [Internet]. Ottawa: Public Health Agency of Canada; 2021 [cited 2022 May 8]. Available from: https://www.canada.ca/en/public-health/ services/immunization/national-advisory-committee-on-immunization-naci/recommendations-usecovid-19-vaccines/mrna-adolescents.html.
- European Medicines Agency. COVID-19 vaccine Spikevax approved for children aged 12 to 17 in EU [Internet]. Amsterdam: European Medicines Agency; 2021 [cited 2022 May 11]. Available from: https://www.ema.europa.eu/en/news/covid-19-vaccine-spikevax-approved-children-aged-12-17-eu.
- Ministerial Correspondence and Public Enquiries Unit, Department of Health and Social Care. JCVI statement on COVID-19 vaccination of children aged 12 to 15 years: 3 September 2021 [Internet]. London: Ministerial Correspondence and Public Enquiries Unit, Department of Health and Social Care; 2021 [cited 2022 May 11]. Available from: https://www.gov.uk/government/publications/jcvi-statement-september2021-covid-19-vaccination-of-children-aged-12-to-15-years/jcvi-statement-on-covid-19-vaccination-ofchildren-aged-12-to-15-years-3-september-2021.
- Ministry of Food and Drug Safety. MFDS expands the vaccination age for Pizer COVID-19 vaccine [Press Release, July 16, 2021]. Cheongju: Ministry of Food and Drug Safety, 2021.
- Korea Diseases Control and Prevention Agency. Updates on COVID-19 in Republic of Korea (as of 3 October 2021). Cheongju: Korea Diseases Control and Prevention Agency, 2021.
- European Centre for Disease Prevention and Control. Questions and answers on COVID-19: vaccines [Internet]. Solna: European Centre for Disease Prevention and Control; 2021 [cited 2022 May 11]. Available from: https://www.ecdc.europa.eu/en/covid-19/questions-answers/questions-and-answers-vaccines.